Oncotype DX Stories

Amy T.

Amy and her medical team determined it was best for her to utilize the Oncotype DX DCIS test.

Amy, a radiology technician, was familiar with Oncotype DX test for invasive breast cancer and she had seen the test help personalize treatment decisions for her patients facing invasive disease.

With her mother diagnosed with breast cancer four years earlier, Amy was determined to receive a mammogram to ensure everything was okay. Following her self-requested mammogram, Amy’s doctor discovered a small tumor that was confined to the milk ducts, known as Ductal Carcinoma in Situ, or DCIS. Amy, a radiology technician, was familiar with Oncotype DX test for invasive breast cancer and she had seen the test help personalize treatment decisions for her patients facing invasive disease. Amy was now grappling with a difficult decision of her own. Her doctors could not decide whether or not she would benefit from radiation.

"It was life altering for me."

Amy and her medical team determined it was best for her to utilize the Oncotype DX DCIS test to help everyone understand her particular case better. Upon receiving her test results, Amy was so relieved to find out that her likelihood of any tumor recurrence was very low.

"It was life altering for me. Everyone should have the knowledge and ability to ask their doctor if Oncotype DX is right for them. We have a right to decide what breast cancer treatment is right for us. Don’t be afraid to be your own advocate."

The information presented on this site is intended to provide patients with newly diagnosed invasive or pre-invasive breast cancer (medically known as Ductal Carcinoma In Situ), as well as their friends and family, an opportunity to hear how others have incorporated the information provided by the Oncotype DX® Recurrence Score® in making treatment decisions with their doctors. The personal stories featured on this site selected by Genomic Health, Inc., which offers the Oncotype DX® tests, are not intended to be representative of patients with breast cancer generally, and should not be considered medical advice. Patients should consult their doctor to determine the best treatment decision for their individual disease.

American Society of Clinical Oncology (ASCO) and ASCO are registered trademarks of ASCO; National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN. ASCO and NCCN do not endorse any product or therapy.